Numerical analysis of time-dependent inhibition kinetics: comparison between rat liver microsomes and rat hepatocyte data for mechanistic model fitting

References

• Albaugh DR, Fullenwider CL, Fisher MB, Hutzler JM. (2012). Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug–drug interactions using plated human cell systems. Drug Metab Dispos 40:1336–44.
   PubMed Web of Science ®Google Scholar
• Arayne MS, Sultana N, Bibi Z. (2005). Grape fruit juice–drug interactions. Pak J Pharm Sci 18:45–57.
   PubMedGoogle Scholar
• Barnaba C, Yadav J, Nagar S, et al. (2016). Mechanism-based inhibition of CYP3A4 by podophyllotoxin: aging of an intermediate is important for in vitro/in vivo correlations. Mol Pharm 13:2833–43.
   PubMedGoogle Scholar
• Bertelsen KM, Venkatakrishnan K, Von Moltke LL, et al. (2003). Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 31:289–93.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu L, Monshouwer M, Fretland AJ. (2011). Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug–drug interactions. Drug Metab Dispos 39:2085–92.
   PubMed Web of Science ®Google Scholar
• Cleland WW. (1975). Partition analysis and the concept of net rate constants as tools in enzyme kinetics. Biochemistry 14:3220–4.
   PubMed Web of Science ®Google Scholar
• Correia MA. (1991). Cytochrome P450 turnover. Meth Enzymol 206:315–25.
   PubMed Web of Science ®Google Scholar
• Fahmi OA, Hurst S, Plowchalk D, et al. (2009). Comparison of different algorithms for predicting clinical drug–drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos 37:1658–66.
   PubMed Web of Science ®Google Scholar
• Fahmi OA, Maurer TS, Kish M, et al. (2008). A combined model for predicting CYP3A4 clinical net drug–drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 36:1698–708.
   PubMed Web of Science ®Google Scholar
• Gertz M, Cartwright CM, Hobbs MJ, et al. (2013). Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug–drug interaction potential. Pharm Res 30:761–80.
   PubMed Web of Science ®Google Scholar
• Grimm SW, Einolf HJ, Hall SD, et al. (2009). The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 37:1355–70.
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Melton RJ, Rumsey JM, et al. (2006). Inhibition of cytochrome P450 3A4 by a pyrimidineimidazole: evidence for complex heme interactions. Chem Res Toxicol 19:1650–9.
   PubMed Web of Science ®Google Scholar
• Kang P, Liao M, Wester MR, et al. (2008). CYP3A4-mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile. Drug Metab Dispos 36:490–9.
   PubMed Web of Science ®Google Scholar
• Kirby BJ, Collier AC, Kharasch ED, et al. (2011). Complex drug interactions of HIV protease inhibitors 1: inactivation, induction and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. Drug Metab Dispos 39:1070–8.
   PubMed Web of Science ®Google Scholar
• Korzekwa K, Tweedie D, Argikar UA, et al. (2014). A numerical method for analysis of in vitro time-dependent inhibition data. Part 2. Application to experimental data. Drug Metab Dispos 42:1587–95.
   PubMed Web of Science ®Google Scholar
• Kotegawa T, Laurijssens BE, Von Moltke LL, et al. (2002). In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J Pharmacol Exp Ther 302:1228–37.
   PubMed Web of Science ®Google Scholar
• Lecluyse EL, Audus KL, Hochman JH. (1994). Formation of extensive canalicular networks by rat hepatocytes cultured in collagen-sandwich configuration. Am J Physiol 266:C1764–74.
   PubMed Web of Science ®Google Scholar
• López-Garcia MP, Dansette PM, Mansuy D. (1994). Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. Biochemistry 33:166–75.
   PubMed Web of Science ®Google Scholar
• Mao J, Johnson TR, Shen Z, Yamazaki S. (2013). Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. Drug Metab Dispos 41:343–52.
   PubMed Web of Science ®Google Scholar
• Mao J, Mohutsky MA, Harrelson JP, et al. (2011). Prediction of CYP3A mediated drug–drug interactions using human hepatocytes suspended in human plasma. Drug Metab Dispos 39:591–602.
   PubMed Web of Science ®Google Scholar
• Mao J, Tay S, Khojasteh CS, et al. (2016). Evaluation of time dependent inhibition assays for marketed oncology drugs: comparison of human hepatocytes and liver microsomes in the presence and absence of human plasma. Pharm Res 33:1204–19.
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Konno Y, Satsukawa M, et al. (2012). Assessment of intestinal availability of various drugs in the oral absorption process using portal vein-cannulated rats. Drug Metab Dispos 40:2231–8.
   PubMed Web of Science ®Google Scholar
• Mcginnity DF, Berry AJ, Kenny JR, et al. (2006). Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab Dispos 34:1291–300.
   PubMed Web of Science ®Google Scholar
• Mohutsky M, Hall SD. (2014). Irreversible enzyme inhibition kinetics and drug–drug interactions. Methods Mol Biol 1113:57–91.
   PubMedGoogle Scholar
• Nagar S, Jones JP, Korzekwa K. (2014). A numerical method for analysis of in vitro time-dependent inhibition data. Part 1. Theoretical considerations. Drug Metab Dispos 42:1575–86.
   PubMed Web of Science ®Google Scholar
• Olkkola KT, Aranko K, Luurila H, et al. (1993). A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53:298–305.
   PubMed Web of Science ®Google Scholar
• Pessayre D, Descatoire V, Konstantinova-Mitcheva M, et al. (1981a). Self-induction by triacetyloleandomycin of its own transformation into a metabolite forming a stable 456 nm-absorbing complex with cytochrome P-450. Biochem Pharmacol 30:553–8.
   PubMed Web of Science ®Google Scholar
• Pessayre D, Konstantinova-Mitcheva M, Descatoire V, et al. (1981b). Hypoactivity of cytochrome P-450 after triacetyloleandomycin administration. Biochem Pharmacol 30:559–64.
   PubMed Web of Science ®Google Scholar
• Pessayre D, Larrey D, Vitaux J, et al. (1982). Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans. Biochem Pharmacol 31:1699–704.
   PubMed Web of Science ®Google Scholar
• Pinto AG, Horlander J, Chalasani N, et al. (2005a). Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein. Br J Clin Pharmacol 59:440–6.
   PubMed Web of Science ®Google Scholar
• Pinto AG, Wang YH, Chalasani N, et al. (2005b). Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther 77:178–88.
   PubMed Web of Science ®Google Scholar
• Polasek TM, Miners JO. (2008). Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants. Br J Clin Pharmacol 65:87–97.
   PubMed Web of Science ®Google Scholar
• Salminen KA, Meyer A, Imming P, Raunio H. (2011). CYP2C19 progress curve analysis and mechanism-based inactivation by three methylenedioxyphenyl compounds. Drug Metab Dispos 39:2283–9.
   PubMed Web of Science ®Google Scholar
• Silverman RB. (1995). Mechanism-based enzyme inactivators. Methods Enzymol 249:240–83.
   PubMed Web of Science ®Google Scholar
• Skett P. (1994). Problems in using isolated and cultured hepatocytes for xenobiotic metabolism/metabolism-based toxicity testing-solutions? Toxicol in Vitro 8:491–504.
   PubMed Web of Science ®Google Scholar
• Sridar C, D'agostino J, Hollenberg PF. (2012). Bioactivation of the cancer chemopreventive agent tamoxifen to quinone methides by cytochrome P4502B6 and identification of the modified residue on the apoprotein. Drug Metab Dispos 40:2280–8.
   PubMed Web of Science ®Google Scholar
• Swift B, Pfeifer ND, Brouwer KL. (2010). Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab Rev 42:446–71.
   PubMed Web of Science ®Google Scholar
• Teng WC, Oh JW, New LS, et al. (2010). Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol 78:693–703.
   PubMed Web of Science ®Google Scholar
• Van LM, Swales J, Hammond C, et al. (2007). Kinetics of the time-dependent inactivation of CYP2D6 in cryopreserved human hepatocytes by methylenedioxymethamphetamine (MDMA). Eur J Pharm Sci 31:53–61.
   PubMed Web of Science ®Google Scholar
• Wang YH, Jones DR, Hall SD. (2005). Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos 33:664–71.
   PubMed Web of Science ®Google Scholar
• Xu L, Chen Y, Pan Y, et al. (2009). Prediction of human drug–drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator. Drug Metab Dispos 37:2330–9.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Urano T, Hiroki S, Shimada T. (1996). Effects of erythromycin and roxithromycin on oxidation of testosterone and nifedipine catalyzed by CYP3A4 in human liver microsomes. J Toxicol Sci 21:215–26.
   PubMedGoogle Scholar
• Yukinaga H, Takami T, Shioyama SH, et al. (2007). Identification of cytochrome P450 3A4 modification site with reactive metabolite using linear ion trap-Fourier transform mass spectrometry. Chem Res Toxicol 20:1373–8.
   PubMed Web of Science ®Google Scholar
• Zhao P, Kunze KL, Lee CA. (2005). Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab Dispos 33:853–61.
   PubMed Web of Science ®Google Scholar